ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics

Bacterial persisters: molecular mechanisms and therapeutic development

Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)

Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistantStaphylococcus aureusimplant-associated osteomyelitis